Medical Treatment of later-stage motor problems of Parkinson Disease

Mayo Clinic Proceedings

Volumn 74, Issue 12, 1999, Pages 1239-1254

  Eric Ahlskog, J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

DRUG EFFICACY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032760352     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.12.1239     Document Type: Review

References (77)

1. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacül. 1997;20:523-530.
2. Ahtskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc. 1996;71:659-670.
3. Ahlskog JE. Neuroprotective strategies in the treatment of Parkinson's disease: clinical evidence. In: LeWitt PA, Oertel WH, eds. Parkinson 's Disease: The Treatment Options. London, England: Martin Dunitz; 1999:93-115.
4. Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet. 1998:351:851-852.
5. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971;46:231-239.
6. Nutt JG. Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med. 1984;310:483488.
7. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to l -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35:949-956.
8. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853-860.
9. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994;662:69-74.
10. Barbato L, Stocchi F, Monge A, et al. The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. 1997;20:394-401.
11. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(suppl 5):S17-S25.
12. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 1998;55(suppl l):l-9.
13. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 1990;27:18-23.
14. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol. 1992;32:776-781.
15. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline.,4/r/! Neurol. 1994;51:1236-1241.
16. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol. 1996; 19:202-212.
17. Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc. 1988;63:876-886.
18. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Längsten JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 1993;43:10361039.
19. Pappert EJ, Buhrfiend C, Lipton JW, Carvey PM, Goetz CG. The stability characteristics of levodopa solution [abstract]. Mov Disord. 1994;9:484.
20. Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol. 1987;44:10061009.
21. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptorpreferring agonist: comparison to other dopamine receptor agonists. Ear J Pharmacol. 1996;312:35-44.
22. Perachon S, Schwanz J-C, Sokoloff P. Binding and functional potencies of bromocriptine, pramipexole, pergolide and ropinirole at Dr D, and D, receptors [abstract]. Neurology. 1998;50(suppl 4): A134.
23. Tulloch IF. Pharmacologie profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997;49(suppl 1):S58-S62.
24. Schachter M. Bedard P, Debono AG, et al. The role of D-1 and D-2 receptors. Nature. 1980;286:157-159.
25. Ahlskog JE, Muenter MD, Bailey PA, Stevens PM. Dopamine agonist treatment of fluctuating parkinsonism: D-2 (controlledrelease MK-458) vs combined D-l and D-2. Arch Neurol. 1992;49:560-568.
26. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs. 1996;5:369-388.
27. Mear JY, Barroche G, de Smet Y, Weber M, Lhermitte F, Agid Y. Pergolide in the treatment of Parkinson's disease. Neurology. 1984:34:983-986.
28. Albani C, Popescu R, Lacher R, Böke-Kuhn K. Single dose response to pramipexole in patients with Parkinson's disease [abstract]. Mov Disord. 1992;7(suppl 1):98.
29. Lieberman A, Olanow CW, Sethi K, et al, Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease [published correction appears in Neurology. 1999;52:435], Neurology. 1998;51:1057-1062.
30. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 1990;39:491-506.
31. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 1983;33:1009-1014.
32. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 1995;45(suppl 3):S13-S21.
33. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord. 1994;9:431-436.
34. Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology. 1997 ;49:1060-1065.
35. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F, 053 Study Group. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3year study. Mov Disord. 1998; 13:46-51.
36. Längsten JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
37. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. / Neural Transm Suppl. 1995;45:225-230.
38. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997; 49:162168.
39. Pinter MM, Pogarell 0, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neural Neurosurg Psychiatry. 1999;66:436-441.
40. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. JNeural Transm Suppl. 1995;45: 231-238.
41. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996:19:234-245.
42. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-47.
43. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neural. 1983;37:95-108.
44. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985;35:749-751.
45. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neural Neurosurg Psychiatry. 1988;51:529-533.
46. Olanow CW. Pergolide/parlodel crossover study [abstract]. Neurology. 1988;38(suppl 1):314.
47. Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Agonist substitution in advanced Parkinson's disease. Neurology. 1989:39:1121-1122.
48. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology. 1999;52:1227-1229.
49. Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Adv Neural. 1996;69: 493-496.
50. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 1993;43:2685-2688.
51. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neural Neumsurg Psychiatry. 1996;60:36-40.
52. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44:913-919.
53. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients, din Neuropharmacol. 1996; 19:222-233.
54. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients [published correction appears in Ann Neural. 1998;44:292]. Ann Neural. 1997;42: 747-755.
55. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51 : 1309-1314.
56. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neural Neurosurg Psychiatry. 1997;63:421 -428.
57. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebocontrolled, multicenter trial. Neurology. 1997;49:1066-1071.
58. Adler CH, Singer C, O'Brien C, et al, Tolcapone Fluctuator Study Group III. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopacarbidopa. Arch Neural. 1998;55:1089-1095.
59. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord. 1999;14:38-44.
60. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol. 1988;! 1:45-55.
61. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc. 1977;52:163-174.
62. Muenter MD, Sharpless NS, Tyce GM. 3-O-methyldopa in Parkinson's disease. Adv Neurol. 1974;5:309-315.
63. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias [letter]. Mov Disord. 1996:11:327-329.
64. Chase TN, Oh JD, Blanche! PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 1998;51(suppl 2):S30-S35.
65. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998;50:1323-1326.
66. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology. 1996;46:1548-1551.
67. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology. 1995;45:753-761.
68. Volkmann J, Sturrn V, Weiss P, et al. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann Neurol. 1998;44:953-961.
69. Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology. 1998;51:850-855.
70. Zhang L, Siddiqui A, Counihan T, Kurlan R. A novel treatment for transient freezing in Parkinson's disease: application of a laser pointer [abstract]. Neurology. 1999;52(suppl 2):A222.
71. Dietz MA, Goetz CO, Stebbins GT. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990;5:243-247.
72. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse. 1994;18:86-93.
73. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology. 1999;52(suppl 3): S10-S13.
74. Lieberman A, Dziatolowski M, Kupersmith M, et al. Dementia in Parkinson disease. Ann Neurol. 1979:6:355-359.
75. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol. 1988:45:260-262.
76. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999:52:1908-1910.
77. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc. 1999;74:371-375.